Biomedica Gruppe公司

骨代謝

心血管疾病

氧化應激

Osteoprotegerin

BNP Fragment*

MDA-oxLDL*

Free soluble Rankl

proANP

Peroxides

Dickkopf-1*

NT-proCNP

Autoantibodies against oxLDL

Sclerostin*

Big Endothelin

Cathepsin K*

Endothelin

Endostatin*

骨質酥鬆症、關(guan) 節炎、骨代謝紊亂(luan) 、腫瘤誘導的骨病

冠狀動脈疾病、shen病、癌症

冠狀動脈疾病、shen病、動脈硬化

骨代謝

應用

Osteoprotegerin （OPG）

心血管疾病評價(jia) 的標記物

Free soluble Rankl (sRankl)

可控製孕酮水平變化導致的乳腺癌及抑製骨腫瘤細胞的進一步惡化。

Dickkopf-1(DKK-1)

減輕病人對骨髓瘤治療的MM應答

Sclerostin

Sclerostin 抗體(ti) 治療，促進骨質形成。

Cathepsin K

心血管疾病

應用

BNP Fragment（8-29）

心血管疾病預後治療檢測的標記物

proANP（1-98）

抗腫瘤治療的新靶點，可預測慢性心衰竭的患者的生存率。

NT-proCNP

可預測創傷(shang) 引起的敗血症發病率

Big Endothelin（1-38）

ET-A受體(ti) 拮抗劑，用於(yu) 改善冠脈內(nei) 皮功能。

ET-B 受體(ti) ，腫瘤免疫治療的靶點

Endothelin（1-21）

Endostatin

內(nei) 源性的血管生成抑製劑，是慢性shen髒病人微血管檢測的可能的標記物

氧化應激

應用

MDA-oxLDL（MDA-oxLDL）

與(yu) 代謝綜合征和冠心病風險檢測相關(guan) ，是急性心肌梗死的影響因子。

Autoantibodies against oxLDL(oLAB)

評價(jia) 藥物對氧化低密度脂蛋白自身抗體(ti) 產(chan) 生的相關(guan) 效應。

Peroxides

骨代謝標記物

在絕經婦女、骨固定引起的骨質流失患者、多重骨髓瘤患者Sclerostin水平顯著升高。經甲狀旁腺素（PTH）和雌性激素持續治療後，血清Sclerostin水平降低。隨著Sclerostin和DKK-1中和抗體(ti) 的開發研究，有望對於(yu) 骨代謝疾病治療，獲得新進展。

Sclerostin ELISA Kit (BI-20492)

檢測方法

夾心ELISA，HRP/TMB顯色係統

樣本

血清、血漿

樣本量

20ul/test，12 x8 test

檢測範圍

0-240pmol/L

靈敏度

2.6pmol/L

孵育時間

過夜/1h/30min

DKK-1和Sclerostins是wnt信號通路的有效的抑製劑，且在成骨細胞的分化過程中發揮重要作用。研究表明，骨形成減少、多發性骨髓瘤或由乳腺癌、前列腺癌、肺癌或關(guan) 節炎引起的骨轉移，都可導致DKK-1水平升高，

Dickkopf-1 ELISA kit (BI-20413)

檢測方法

夾心ELISA，HRP/TMB 顯色係統

樣本

血清、細胞培養(yang) 上清

樣本量

20ul/test，12 x8 test

檢測範圍

0-160pmol/l

靈敏度

1.7pmol/L

孵育時間

2h/1h/30min

sRankl 是（NF）-KB配體(ti) 的可溶性受體(ti) 激活因子，是成熟破骨細胞形成的主要刺激因子，對於(yu) 破骨細胞的存活具有重要作用。Rankl 激活位於(yu) 成骨細胞及樹突細胞其特異性受體(ti) Rank。

sRankl ELISA kit (BI-20452)

檢測方法

夾心ELISA，檢測係統：AP/ NADPH

樣本

血清、血漿、細胞培養(yang) 上清

樣本量

100ul/test，12 x8 test

檢測範圍

0-2pmol/L

靈敏度

0.02pmol/L

孵育時間

過夜/1h/30min

OPG是Rankl的可溶性分泌受體(ti) ，可抑製破骨細胞的發育。

Osteoprotegerin(OPG) ELISA kit (BI-20403)

檢測方法

夾心ELISA，檢測係統：HRP/TMB

樣本

血清、血漿

樣本量

20ul/test，12 x8 test

檢測範圍

0-20pmol/L

靈敏度

0.07 pmol/L

孵育時間

3h/1h/30min

Cathepsin K 是破骨細胞活化、重吸收中大量表達的合成蛋白。Cathepsin K含量的升高，反映了sRankl 激活破骨細胞的能力。

Cathepsin K ELSIA kit (BI-20432)

檢測方法

夾心ELISA，檢測係統：HRP/TMB

樣本

血清、細胞培養(yang) 上清

樣本量

50ul/test，12 x8 test

檢測範圍

0-300pmol/l

靈敏度

1.1pmol/L

孵育時間

過夜/30min

參考文獻

試驗設計

結論

Association of sclerostin levels with the severity of aortic valve calcification. Koos R et al., JACC ; 2011; 57, 14

心髒主動脈瓣硬化患者

樣本：115例

與(yu) 正常人群相比心髒主動脈瓣硬化（AVC）患者，sclerostin水平顯著升高。AVC疾病的嚴(yan) 重程度與(yu) sclerostin血清水平相關(guan) 。

Sclerostin and Dickkopf-1 in Renal Osteodystrophy. Cejka D et al., Clin J Am Soc  Nephrol; 2011; 6: 877-882

慢性shen髒病患者（CKD-5D）

樣本：60例

針對高轉換性骨代謝的CKD-5D病人除了檢測IPTH外，還可檢測Sclerostin作為(wei) 評價(jia) 指標。

Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemo-dialysis patients. Cejka D et al.,  Nephrol DiaTransplant; 2012; 27: 226-230

血透患者

樣本：76例

對照樣本：45例

血透患者的sclerostin水平，顯著高於(yu) 對照樣本。骨密度（BMD）與(yu) 血清sclerostin水平呈正相關(guan) 。

Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. Gennari L et al., J Clin Endo Metab; 2012; 97: 1737-1744

II型糖尿病患者（DM2）：40例

I型糖尿病患者（DM1）：43例

對照樣本：83人

研究表明，DM2患者sclerostin水平升高。此外，由PTH 抑製轉錄sclerostin可能在DM1和DM2病人減弱。

Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relation-ship with bone density and arterial stiffness. Thambiah S et al., Calcif Tissue Int; 2012; 90(6): 473-480

慢性shen髒疾病（CKD）3B期患者32例

慢性shen髒疾病（CKD）4期患者：45例

Sclerostin水平與(yu) 年齡成正相關(guan) 。男性Sclerostin水平要高於(yu) 女性。shen小球濾過率（GFR）與(yu) Sclerostin水平呈負相關(guan) 。骨密度（BMD）與(yu) 血清sclerostin水平呈正相關(guan) 。Wnt 信號通路可能在代謝紊亂(luan) 疾病中發揮重要作用。

2013 ISN 研討會(hui) 會(hui) 議論文（骨病與(yu) shen病）

試驗設計

結論

Bone density and arterial stiffness are related to circulating sclerostin and Dickkopf-1 (DKK1) in pre-dialysis chronic kidney disease (CKD) patients. Goldsmith D et al.,  Poster # 15

血透前患者：

CKD 3B期和4期患者：77例

該研究為(wei) ：Wnt 信號通路抑製劑（Sclerostin 及DKK-1）在確定骨骼和血管功能及慢性shen髒病人（CKD）結構中發揮重要的作用，提供有力證據。

Circulating sclerostin levels and vascular calcification in chronic kidney disease: A

complex relationship. Claes KJ et al.,Poster # 91

無機代謝縱向研究：154例

AC患者表達高水平的sclerostin。反之，sclerostin較低。後續的臨(lin) 床和實驗研究需進一步闡明sclerostin是否在保護血管鈣化中起到重要作用。

Sclerostin and DKK-1 levels in pre-dialysis CKD patients. Behts G et al.;  Poster # 89

觀測性研究：

149病人（慢性shen病患者CKD 1-5期，男性：81例，60±16歲，22位糖尿病患者）

隨著shen病嚴(yan) 重程度，sclerostin（非DKK-1）水平升高。

Low PTH and high circulating sclerostin levels are independently associated with low bone specific alkaline phosphatase levels in hemodialysis patients. Viaene L et al., Poster # 90

血透病人：100例

Sclerostin水平的升高是糖尿病患者、shen功能不全（RRF）、急性胰腺炎(BSAP)患者的獨立的風險因素。Sclerostin水平的高表達及PTH 的低表達與(yu) BSAP相關(guan) ，反映了低水平的骨質形成。

*作者及參考文獻

疾病

研究群體(ti) /試驗設計

主要結論

Sclerostin: another bone-related protein related to all-cause mortality in haem dialysis? Viaene L et al., Nephrol Dial Transplant, 2013; 10.1093/ndt/gft039

 shen病

血透患者（觀察隨後637天個(ge) 體(ti) 的生存率），100例

血透患者Sclerostin水平的升高與(yu) 提高生存率相關(guan) 。

The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD. Pelletier S et al., Clin J Am Soc Nephrol, 2013; 8: 819-823

慢性shen病患者（CKD）：90例

在CKD III 期：Sclerostin水平開始升高。

Sclerostin and DKK-1 levels in pre-dialyisis CKD patients. Behets G et al., Nephrol Dial Transplant, 2012; 27: ii36-ii37

慢性shen病患者（橫向觀察性研究）：149例

隨著shen病嚴(yan) 重程度，sclerostin（非DKK-1）水平升高。

Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Cejka D et al., Nephrol Dial Trans-plant, 2012; 27: 226-230

血透患者（橫向研究）：76例

血透患者的sclerostin水平，顯著高於(yu) 對照樣本。

Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Gaudio A et al., J Clin Endocrinol Metab, 2012; 97: 3744–3750

糖尿病

絕經婦女II型糖尿病患者（橫向研究）：40例

與(yu) 之前研究結果一致，II型糖尿病患者sclerostin水平高於(yu) 對照樣本及骨轉換標記物水平低於(yu) 對照樣本。

Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes.

Gennari L et al., J Clin Endo Metab, 2012; 97: 1737-1744

I型和II型糖尿病患者（橫向研究）

DM1：43例   DM2：40例

研究表明：II型糖尿病患者sclerostin水平升高。

Association of Sclerostin levels with the severity of aortic valve calcification. Koos et al., JACC, 2011; 57, 14

心髒主動脈瓣硬化

主動脈瓣患者（橫向研究）：115例

與(yu) 正常健康對照樣本群體(ti) 比較，AVC患者sclerostin水平升高。

Serum Sclerostin levels are associated with aortic valve calcification in prevalent ha-emodialysis patients. Türkvatan A et al., Nephrol Dial Transplant, 2013; 28: i19–i21

血透患者：101例

AVC患者sclerostin血清水平顯著高於(yu) 未鈣化的AVC患者相比，。

Circulating Sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Thambiah S et al., Calcif Tissue Int, 2012; 90(6): 473-480

動脈硬化

慢性shen病患者CKD 3BQ期和4期：77例

shen小球濾過率（GFR）與(yu) Sclerostin水平呈負相關(guan) 。Wnt 信號通路可能在代謝紊亂(luan) 疾病中發揮重要作用。

檢測特點

BI-20413

BI-20412

孵育時間

2h/1h/30min

孵育過夜

樣品處理

直接測定

需要1:4稀釋

標準品範圍

0-160pmol/L

0-50pmol/L

1

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin

and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A

Randomized, Head-to-Head Clinical Trial. Athanasioses D. Anastasilakis, et al.

J. Clin. Endocrinol. Metab., Aug 2013; 98: 3206 - 3212.

2

Elevated Serum Dickopff-1 Levels Increase Risk of Hip and Vertebral Fracture in Older Caucasian Women. Aarthi Arasu,et al. Endocr. Rev., Jun 2013; 34: SAT-224.

3

Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Diederik P C de Rooy,et al. Ann Rheum Dis, May 2013; 72: 769 - 775.

4

High dickkopf-1 levels in sera and leukocytes from children with 21-

hydroxylase deficiency on chronic glucocorticoid treatment. Giacomina Brunetti,et al. Am J Physiol Endocrinol Metab, Mar 2013; 304: E546 - E554.

5

Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. D Gatti,et al. J Bone Miner Res, Nov 2012; 27(11): 2259-63. 

6

Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., Oct 2012; 97: 3744 - 3750.

7

Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans

Cell Histiocytosis. Polyzois Makras,et al. J. Clin. Endocrinol. Metab., Apr 2012; 97: E618 - E621

8

High level of functional dickkopf-1 predicts protection from syndesmophyte

formation in patients with ankylosing spondylitis. Gisela Ruiz Heiland,et al. Ann Rheum Dis, Apr 2012; 71: 572 - 574. 

9

Assessment of circulating Dickkopf-1 with a new two-site immunoassay in

healthy subjects and women with breast cancer and bone metastases. N Voorzanger-Rousselot, et al. Calcif Tissue Int, May 1, 2009; 84(5): 348-354

10

Circulating Dickkopf-1 and Radiological Progression in Patients with Early

Rheumatoid Arthritis Treated with Etanercept. Patrick Garnero,et al. J Rheumatol, Oct 2008.

11

Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss. Agostino Gaudio,et al. J. Clin. Endocrinol. Metab., May 2010; 95: 2248 - 2253.

12

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone

Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma. Evangelos Terpos,et al. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 425.

13

The Effect of Zoledronic Acid on Serum Dickkopf-1, Osteoprotegerin, and RANKL

in Patients with Paget's Disease of Bone. S A Polyzos, et al. Horm Metab Res, Aug 2009 

14

Glucocorticoids Attenuate the Stimulatory Effect on Bone Formation by

Bortezomib. Thomas Lund,et al. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 5183. 

參考文獻

試驗設計

結論

Elevated plasma levels of endostatin are associated with chronic kidney disease. J Chen, LL Hamm, et al.Am J Nephrol, Jan 2012; 35(4): 335-340

CKD患者：201例

對照群體(ti) ：201例

血漿Endostain的升高，與(yu) CKD患者高度相關(guan) 。進一步研究及臨(lin) 床實驗已批準驗證Endostain與(yu) CKD發病風險之間的關(guan) 係及研究針對Endostain的新的幹預措施，以減少CKD的發病風險。

Early-onset coronary artery disease after pediatric kidney transplantation: implicatingthe angiogenesi inhibitor, endostatin. CW Iqbal,et al. Am Surg, Jun 2011; 77(6): 731-735

接受shen移植者：12例

接受肝移植者：8例

與(yu) 肝移植者及健康對照個(ge) 體(ti) 相比，shen移植者Endostain水平升高。Endostain在shen移植後引起的動脈硬化疾病中發揮重要作用，且Endostain可能作為(wei) 動脈硬化疾病檢測的生物標記物。

Immobilized kidney 28-kDa endostatin-related (KES28kDa) fragment

promotes endothelial cell survival.MH Bellini, et al.

Am J Nephrol, Jan 2010; 31(3): 255-261

可溶性和固定化的Endostatin 對細胞活性影響。

研究表明：由急性shen損傷(shang) （AKI）引起的局部合成28KD相關(guan) 的Endostain片段，對於(yu) 內(nei) 皮細胞的存活，發揮重要作用。

Endostatin and angiosestatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Neel R. Sodha, et al.Am J Physiol Heart Circ Physiol, Feb 2009; 296: H428-H434

經動脈搭橋術手術病人的心肌組織

（非糖尿病例：11例 ，II型糖尿病：10例）

研究表明：在促血管新生治療中，Endostain是潛在的治療靶點，且糖尿病患者可見血管損傷(shang) 。

A defective angiogenesis in chronic kidney disease.N Futrakul,et al. Jan 2008; 30(2): 215-217

通過研究血管生成因子、Endostain、VEGF、抗血管生成因子之間的平衡，來反映血管損傷(shang) 程度。

慢性shen病(CKD)患者Endostain及CEC非正常升高，而VEGF表現為(wei) 缺乏。

1

Infliximab Treatment Increases Left Ventricular Ejection Fraction in Patients with Rheumatoid Arthritis: Assessment of Heart Function by Echocardiography, Endothelin 1, Interleukin 6, and NT-pro Brain Natriuretic Peptide. PRZEMYSLAW J,et al. J Rheumatol, Apr 2012; 39: 701 - 706.

2

Left Ventricular Function Impairment in Patients With Normal-Weight Obesity:

Contribution of Abdominal Fat Deposition, Profibrotic State, Reduced Insulin

Sensitivity, and Proinflammatory Activation. Wojciech Kosmala,et al. Circ Cardiovasc Imaging, May 2012; 5: 349 - 356.

3

Prognostic value of left atrial expansion index and exercise-induced change in atrial natriuretic peptide as long-term predictors of atrial fibrillation recurrence..Malini Govindan,et al. Europace, Sep 2012; 14: 1302 - 1310.

4

Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl

oxidase? Begoña López,et al. Cardiovasc Res, Jul 2013; 99: 111 - 120. 

5

High-sensitivity troponin assay improves prediction of cardiovascular risk in

patients with cerebral ischaemia. Raoul Stahrenberg,et al. J. Neurol. Neurosurg. Psychiatry, May 2013; 84: 479 - 487.

6

Translational phases of evidence in a prognostic biomarker: a systematic review and meta-analysis of natriuretic peptides and the prognosis of stable coronary disease. Shailen Sutaria,et al. Heart, Apr 2012; 98: 615 - 622. 

7

Prognostic impact of body mass index in patients undergoing coronary artery

bypass surgery. Shih-Hsien Sung,et al. Heart, Apr 2011; 97: 648 - 654.

8

Troponin T, N-terminal pro natriuretic peptide and a patent ductus arteriosesus

scoring system predict death before discharge or neurodevelopmental outcome at 2 years in preterm infants. Afif F EL-Khuffash,et al. Arch. Dis. Child. Fetal Neonatal Ed., Mar 2011; 96: F133 - F137. 

9

Multidimensional assessment of older people with asthma and COPD: clinical

management and health status. Vanessa M. McDonald,et al. Age Ageing, Jan 2011; 40: 42 – 49

10

Diagnostic value of NT-proBNP in identifying aortic stenosis patients with heart failure. C Wu,et al. Zhonghua Xin Xue Guan Bing Za Zhi, Jul 2010; 38(7): 579-83.

11

Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right

ventricular function and outcome after mitral valve replacement? Shantanu Pande,et al. Interact CardioVasc Thorac Surg, Sep 2009; 9: 421 - 425

12

Pulmonary arterial hypertension in rheumatic mitral stenosis: does it affect right

ventricular function and outcome after mitral valve replacement? Shantanu Pande,et al. Interactive CardioVascular and Thoracic Surgery, Sep 2009; 9: 421 - 425.

13

Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular

function in patients with symptomatic heart failure. John K. Kjekshus,et al. Eur J Heart Fail, Aug 2009; 11: 771 – 778

14

Prevalence of Left Ventricular Diastolic Dysfunction in a General Population. Tatiana Kuznetsova,et al. Circ Heart Fail, Mar 2009; 2: 105 - 112.

1

Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Clerico A et al., Am J Physiol Heart Circ Physiol 2011; 301: H12-H20

2

Comparison of Pleural Fluid N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic-32 Peptide Levels. Long AC et al., Chest 2010; 137: 1369-1374

3

N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure. Hermann-Arnhof K et al., Cl inical Chemistry 2005; 51:138-143

4

Natriuretic Peptides: New Players in Energy Homeostasis.  Moro C and Smith RH, Diabetes 2009; 58: 27-26

5

Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Jarai R et al., Eur Heart J 2004; 26: 250-256

6

Natriuretic peptides: Markers or modulators of cardiac hypertrophy? Gardner DG, Trends Endocrinol Metab 2003; 14: 411-416

7

Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Berger R et al, Eur J Clin Invest 2005, 35, 24-31

8

Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Miyashita K et al., Diabetes 2009; 58: 2880-2892

9

Processing of Pro–B-Type Natriuretic Peptide: Furin and Corin as Candidate Convertases. Semenov AG et al., Clin Chem. 2010; 56:1166-1176

1

C4d deposition is associated with inferior kidney allograft outcome independ.of cellular rejection. Regele H. et al., Nephrol Dial Transplant. 2001, 16(10): 2058-2066.

2

Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. Böhmig GA et al., J Am Soc Nephrol. 2002, 13(4): 1091-1099.

3

[C4d]FlowPRA screening—a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Wahrmann M et al., Hum Immunol, 2005, 66(5): 526-534

4

Pivotal role of complement-fixing HLA alloantibodies in presensitized kidney allograft recipients. Wahrmann M et al., Am J Transplant, 2006, 6: 1033-1041.

5

In vitro detection of C4d-fixing HLA alloantibodies: associations with capillary C4d deposition in kidney allografts. Bar G et al., Am J Transplant, 2008, 8(1): 41-49

6

Antibodies, isotypes and complement in allograft rejection. Böhmig GA et al., Curr Opin Organ

Transplant, 2008, 13(4): 411-418

7

Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Bar G et al., Transpl Int. 2013; 26(2): 121-130.

8

Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts. Lawrence C et al., Transplantation 2013 Jan 27; 95(2): 341-346.

9

Modified solid-phase alloantibody detection for improved crossmatch prediction. Wahrmann M et al., Hum Immunol. 2013 Jan; 74(1): 32-40.

類別

貨號

名稱

規格

骨代謝係列

BI-20492

Sclerostin (SOST) ELISA 

1 Kit

BI-20413 

DKK-1 ELISA 

1 Kit

BI-20432 

Cathepsin K ELISA Kit

1 Kit

BI-20403

OPG ELISA

1 Kit

BI-20452

sRANKL ELISA

1 Kit

心血管疾病

BI-20742 

Endostatin ELISA

1 Kit

BI-20082H

Big Endothelin-1 ELISA

1 Kit

BI-20052

Endothelin ELISA

1 Kit

BI-20872 

NT-proCNP ELISA

1 Kit

BI-20852W

BNP Fragment ELISA

1 Kit

SK-1204

NT-proBNP ELISA

1 Kit

BI-20892

proANP ELISA

1 Kit

動脈硬化

氧化應激

BI-20032

Anti-Oxidized LDL (oLAB) ELISA

1 Kit

BI-5007

OxyStat Assay (Peroxides)ELISA

1 Kit

BI-20022

MDA-oxLDL ELISA

1 Kit

傳(chuan) 染病

BI-21032 

Borrelia lgG ELISA

1 Kit

BI-21042

Borrelia lgM ELISA

1 Kit

BI-3501 

Rheumatoid Factor Stripper

1 Kit

細胞增殖

BI-5000

EZ4U Cell Proliferation Assay

1 Kit

抗體(ti)

BI-RC4D

Polyclonal Anti-human C4d antibody

200ul

BI-RC4D-FITC

Polyclonal Anti-human C4d FITC Antibody

100 µl

BI-RC4D-PE

Polyclonal Anti-human C4d PE Antibody

50 µl